• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 144 filed by Nektar Therapeutics

    2/18/26 3:15:17 PM ET
    $NKTR
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $NKTR alert in real time by email
    Form 144 Filer Information UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Form 144

    NOTICE OF PROPOSED SALE OF SECURITIES
    PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933

    FORM 144

    144: Filer Information

    Filer CIK
    0001789857
    Filer CCC
    XXXXXXXX
    Is this a LIVE or TEST Filing? Radio button checked LIVE Radio button not checked TEST

    Submission Contact Information

    Name
    Phone
    E-Mail Address

    144: Issuer Information

    Name of Issuer
    NEKTAR THERAPEUTICS
    SEC File Number
    000-24006
    Address of Issuer
    455 MISSION BAY BOULEVARD SOUTH
    SAN FRANCISCO
    CALIFORNIA
    94158
    Phone
    4154825300
    Name of Person for Whose Account the Securities are To Be Sold
    Zalevsky Jonathan
    See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

    Relationship to Issuer
    Officer

    144: Securities Information

    Title of the Class of Securities To Be SoldName and Address of the BrokerNumber of Shares or Other Units To Be SoldAggregate Market ValueNumber of Shares or Other Units OutstandingApproximate Date of SaleName the Securities Exchange
    Common
    Fidelity Brokerage Services LLC
    900 Salem Street
    Smithfield � RI � 02917
    18013139.682034158902/18/2026
    NASDAQ


    Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

    144: Securities To Be Sold

    Title of the ClassDate you AcquiredNature of Acquisition TransactionName of Person from Whom AcquiredIs this a Gift?Date Donor AcquiredAmount of Securities AcquiredDate of PaymentNature of Payment *
    Common02/13/2026Restricted Stock VestingIssuerCheckbox not checked18002/13/2026Compensation

    * If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



    Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

    144: Securities Sold During The Past 3 Months

    Name and Address of SellerTitle of Securities SoldDate of SaleAmount of Securities SoldGross Proceeds
    Jonathan Zalevsky
    455 Mission Bay Boulevard South
    San Francisco � CA � 94158
    Common11/25/2025115768052.89
    Jonathan Zalevsky
    455 Mission Bay Boulevard South
    San Francisco � CA � 94158
    Common01/20/20263867137946.37

    144: Remarks and Signature

    Remarks
    Sale includes an amount necessary to cover a tax obligation resulting from the settlement of a vested equity award distribution.
    Date of Notice
    02/18/2026

    ATTENTION:

    The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
    Signature
    /s/Wade Moss, as a duly authorized representative of Fidelity Brokerage Services LLC, as attorney-in-fact for Jonathan Zalevsky

    ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

    Get the next $NKTR alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $NKTR

    DatePrice TargetRatingAnalyst
    2/10/2026Mkt Perform → Outperform
    William Blair
    11/26/2025$102.00Buy
    Citigroup
    6/24/2025$60.00 → $100.00Buy
    BTIG Research
    6/24/2025$6.50 → $120.00Buy
    H.C. Wainwright
    4/11/2025$2.00Hold → Buy
    Jefferies
    3/14/2025$6.00Perform → Outperform
    Oppenheimer
    1/8/2025$4.00Buy
    B. Riley Securities
    12/10/2024$6.50Buy
    H.C. Wainwright
    More analyst ratings

    $NKTR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief R&D Officer Zalevsky Jonathan sold $13,140 worth of shares (180 units at $73.00), decreasing direct ownership by 0.84% to 21,174 units (SEC Form 4)

    4 - NEKTAR THERAPEUTICS (0000906709) (Issuer)

    2/20/26 7:10:29 PM ET
    $NKTR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    President & CEO Robin Howard W sold $30,879 worth of shares (423 units at $73.00), decreasing direct ownership by 0.56% to 75,489 units (SEC Form 4)

    4 - NEKTAR THERAPEUTICS (0000906709) (Issuer)

    2/20/26 7:10:10 PM ET
    $NKTR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief R&D Officer Zalevsky Jonathan sold $137,936 worth of shares (3,867 units at $35.67), decreasing direct ownership by 15% to 21,354 units (SEC Form 4)

    4 - NEKTAR THERAPEUTICS (0000906709) (Issuer)

    1/22/26 7:31:42 PM ET
    $NKTR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NKTR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Nektar Therapeutics upgraded by William Blair

    William Blair upgraded Nektar Therapeutics from Mkt Perform to Outperform

    2/10/26 11:48:14 AM ET
    $NKTR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Citigroup initiated coverage on Nektar Therapeutics with a new price target

    Citigroup initiated coverage of Nektar Therapeutics with a rating of Buy and set a new price target of $102.00

    11/26/25 8:36:15 AM ET
    $NKTR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BTIG Research reiterated coverage on Nektar Therapeutics with a new price target

    BTIG Research reiterated coverage of Nektar Therapeutics with a rating of Buy and set a new price target of $100.00 from $60.00 previously

    6/24/25 2:02:55 PM ET
    $NKTR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NKTR
    SEC Filings

    View All

    SEC Form 144 filed by Nektar Therapeutics

    144 - NEKTAR THERAPEUTICS (0000906709) (Subject)

    2/18/26 3:15:17 PM ET
    $NKTR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 8-K filed by Nektar Therapeutics

    8-K - NEKTAR THERAPEUTICS (0000906709) (Filer)

    2/12/26 8:23:06 PM ET
    $NKTR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 424B5 filed by Nektar Therapeutics

    424B5 - NEKTAR THERAPEUTICS (0000906709) (Filer)

    2/10/26 4:24:04 PM ET
    $NKTR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NKTR
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Nektar to Announce Financial Results for the Fourth Quarter and Year-Ended 2025 on Thursday, March 12, 2026, After Close of U.S.-Based Financial Markets

    SAN FRANCISCO, Feb. 26, 2026 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the fourth quarter and year-ended December 31, 2025 on Thursday, March 12, 2026, after the close of U.S.-based financial markets. Howard Robin, President and Chief Executive Officer, will host a conference call to review the results beginning at 5:00 p.m. Eastern Time/2:00 p.m. Pacific Time. This press release and live audio-only webcast of the conference call can be accessed through a link that is posted on the Home Page and Investors section of the Nektar web

    2/26/26 6:00:00 PM ET
    $NKTR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Nektar Therapeutics to Participate in Two Investor Conferences in March

    SAN FRANCISCO, Feb. 24, 2026 /PRNewswire/ -- Nektar Therapeutics (NASDAQ:NKTR) today announced that company management will be participating in the TD Cowen 46th Annual Health Care Conference taking place March 2-4, 2026 in Boston and the 2026 Jefferies Biotech on the Beach Summit taking place March 9-11, 2026 in Miami. TD Cowen 46th Annual Health Care Conference in Boston on Wednesday, March 4, 2026 – webcast of the presentation to be available at 9:10 a.m. Eastern Time / 6:10 a.m. Pacific Time – link here 2026 Jefferies Biotech on the Beach Summit in Miami – March 9-11, 2026 –

    2/24/26 6:00:00 PM ET
    $NKTR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Alopecia Areata Market Set to Expand by 2036, Due to the Emergence of Novel Drug Classes Such as OX40L Inhibitors, IL-2 Inhibitors, IL-7Rα, and Others | DelveInsight

    The alopecia areata market is expected to grow significantly as awareness of the condition increases, potentially expanding further in the coming years, supported by rising prevalence. Additionally, the launch of emerging therapies such as RINVOQ (AbbVie), Bempikibart (Q32 Bio), Coacillium (Legacy Healthcare), ALM 223 (Almirall), Amlitelimab (Sanofi), HCW9302 (HCW Biologics), ALY-101 (ALYS Pharmaceuticals), DR-01 (Dren Bio), Rezpegaldesleukin (Nektar Therapeutics), and others will further propel the market growth.LAS VEGAS, Feb. 19, 2026 /PRNewswire/ -- Recently published Alopecia Areata Market Insights report includes a comprehensive understanding of current treatment practices, alopecia ar

    2/19/26 5:31:00 PM ET
    $ABBV
    $HCWB
    $INCY
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Commercial Physical & Biological Resarch

    $NKTR
    Leadership Updates

    Live Leadership Updates

    View All

    DiaMedica Therapeutics Appoints Dr. Lorianne Masuoka as Chief Medical Officer

    Executive with Strong Track Record in Advancing Pipelines Through Clinical Development DiaMedica Therapeutics Inc. (NASDAQ:DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and cardio-renal disease, announced today the appointment of Lorianne Masuoka, M.D. as Chief Medical Officer. Dr. Masuoka is a board-certified neurologist with more than 25 years of experience and a successful track record of managing clinical programs from early stage to drug approvals and strategic alliances. "We are delighted to have Lorianne join our executive leadership team," said Rick Pauls, DiaMedica's President and Chief Executive Officer. "Sh

    1/22/24 8:23:00 AM ET
    $DMAC
    $MRNS
    $NKTR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BigHat Biosciences Appoints Rob Chess, Serial Entrepreneur, to its Board of Directors

    BigHat Biosciences, a biotechnology company designing safer, more effective next-generation antibody therapies for patients using machine learning and synthetic biology, today announced that Rob Chess has been elected to BigHat's board of directors. Rob brings valuable experience in corporate biotech leadership and business strategy, from having led innovative and diverse teams from inception to successful exits to serving on the boards of multiple private and public life sciences companies. "We look forward to leveraging Rob's deep expertise in drug discovery and development to accelerate our work creating better antibody therapies for patients," said Mark DePristo, PhD., BigHat's CEO and

    5/11/22 8:01:00 AM ET
    $NKTR
    $TWST
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    Nektar Therapeutics Strengthens Board of Directors with Appointment of Diana M. Brainard, M.D.

    SAN FRANCISCO, Nov. 15, 2021 /PRNewswire/ -- Nektar Therapeutics (NASDAQ:NKTR) today announced it has appointed Diana M. Brainard, M.D., as an independent director to its Board of Directors. Dr. Brainard brings over two decades of experience working in the healthcare sector and academia to Nektar. She currently serves as Chief Executive Officer (CEO) of AlloVir, Inc., a leading late clinical stage cell therapy company with a focus on restoring natural immunity against life-threatening viral diseases in pediatric and adult patients with weakened immune systems. "We are very ple

    11/15/21 8:30:00 AM ET
    $NKTR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NKTR
    Financials

    Live finance-specific insights

    View All

    Nektar to Announce Financial Results for the Fourth Quarter and Year-Ended 2025 on Thursday, March 12, 2026, After Close of U.S.-Based Financial Markets

    SAN FRANCISCO, Feb. 26, 2026 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the fourth quarter and year-ended December 31, 2025 on Thursday, March 12, 2026, after the close of U.S.-based financial markets. Howard Robin, President and Chief Executive Officer, will host a conference call to review the results beginning at 5:00 p.m. Eastern Time/2:00 p.m. Pacific Time. This press release and live audio-only webcast of the conference call can be accessed through a link that is posted on the Home Page and Investors section of the Nektar web

    2/26/26 6:00:00 PM ET
    $NKTR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    New REZOLVE-AD Maintenance Data in Atopic Dermatitis Demonstrate Rezpegaldesleukin Resulted in Durable and New Responses Across Key Disease Measurements with Both Monthly and Quarterly Dosing

    71% and 83% of patients maintained EASI-75 responses and 85% and 63% maintained vIGA-AD 0/1 responses with 24 µg/kg monthly and quarterly dosing, respectively Meaningful improvement in responses observed across key efficacy endpoints at week 52 with both monthly and quarterly dosing, including an up to 5-fold increase in EASI-100 response rates Favorable safety profile consistent with previously reported results for rezpegaldesleukin Durability of maintained response rates supports advancement to pivotal Phase 3 program evaluating both monthly and quarterly maintenance dosing Data validate novel first-in-class regulatory T-cell mechanism as a potential best-in-class immune-modulator Confere

    2/10/26 7:00:00 AM ET
    $NKTR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Nektar to Hold Conference Call to Discuss Topline Results from the 36-Week Maintenance Period for its REZOLVE-AD Phase 2b Study of Rezpegaldesleukin in Atopic Dermatitis on February 10, 2026

    SAN FRANCISCO, Feb. 9, 2026 /PRNewswire/ -- Nektar Therapeutics (NASDAQ:NKTR), a clinical-stage biotechnology company focused on the development of novel immunology therapies, today announced it will host an investor call and live webcast to review topline results from the 36-week maintenance period of the ongoing Phase 2b REZOLVE-AD clinical trial of investigational rezpegaldesleukin, a regulatory T-cell (Treg) proliferator, for moderate-to-severe atopic dermatitis on Tuesday, February 10, 2026 at 8:00 am ET / 5:00 am PT.  Conference Call The results will be provided in a mo

    2/9/26 4:15:00 PM ET
    $NKTR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NKTR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Nektar Therapeutics

    SC 13G - NEKTAR THERAPEUTICS (0000906709) (Subject)

    11/14/24 12:17:04 PM ET
    $NKTR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Nektar Therapeutics

    SC 13G/A - NEKTAR THERAPEUTICS (0000906709) (Subject)

    11/14/24 9:18:10 AM ET
    $NKTR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Nektar Therapeutics

    SC 13G - NEKTAR THERAPEUTICS (0000906709) (Subject)

    3/15/24 4:18:49 PM ET
    $NKTR
    Biotechnology: Pharmaceutical Preparations
    Health Care